A Mechanism of Resistance to Antibody-Targeted Immune Attack.

Abstract:

:Targeted monoclonal antibody therapy is a promising therapeutic strategy for cancer, and antibody-dependent cell-mediated cytotoxicity (ADCC) represents a crucial mechanism underlying these approaches. The majority of patients have limited responses to monoclonal antibody therapy due to the development of resistance. Models of ADCC provide a system for uncovering immune-resistance mechanisms. We continuously exposed epidermal growth factor receptor (EGFR+) A431 cells to KIR-deficient NK92-CD16V effector cells and the anti-EGFR cetuximab. Persistent ADCC exposure yielded ADCC-resistant cells (ADCCR1) that, compared with control ADCC-sensitive cells (ADCCS1), exhibited reduced EGFR expression, overexpression of histone- and interferon-related genes, and a failure to activate NK cells, without evidence of epithelial-to-mesenchymal transition. These properties gradually reversed following withdrawal of ADCC selection pressure. The development of resistance was associated with lower expression of multiple cell-surface molecules that contribute to cell-cell interactions and immune synapse formation. Classic immune checkpoints did not modulate ADCC in this unique model system of immune resistance. We showed that the induction of ADCC resistance involves genetic and epigenetic changes that lead to a general loss of target cell adhesion properties that are required for the establishment of an immune synapse, killer cell activation, and target cell cytotoxicity.

journal_name

Cancer Immunol Res

authors

Aldeghaither DS,Zahavi DJ,Murray JC,Fertig EJ,Graham GT,Zhang YW,O'Connell A,Ma J,Jablonski SA,Weiner LM

doi

10.1158/2326-6066.CIR-18-0266

subject

Has Abstract

pub_date

2019-02-01 00:00:00

pages

230-243

issue

2

eissn

2326-6066

issn

2326-6074

pii

2326-6066.CIR-18-0266

journal_volume

7

pub_type

杂志文章
  • B cell-Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer.

    abstract::Pancreatic ductal adenocarcinoma (PDA) is an aggressive malignancy characterized by a paucity of tumor-proximal CD8+ T cells and resistance to immunotherapeutic interventions. Cancer-associated mechanisms that elicit CD8+ T-cell exclusion and resistance to immunotherapy are not well-known. Here, using a Kras- and p53-...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-19-0349

    authors: Mirlekar B,Michaud D,Lee SJ,Kren NP,Harris C,Greene K,Goldman EC,Gupta GP,Fields RC,Hawkins WG,DeNardo DG,Rashid NU,Yeh JJ,McRee AJ,Vincent BG,Vignali DAA,Pylayeva-Gupta Y

    更新日期:2020-03-01 00:00:00

  • Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors.

    abstract::Anti-Programed Death 1 (PD-1) is standard immunotherapy for multiple cancers, and the expression of one of its ligands, PD-L1, has been described in germ cell tumors (GCT). Neither the clinical activity of anti-PD-1 nor the incidence of an immunoresponsive tumor microenvironment has been described for GCTs. A patient ...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-16-0087

    authors: Shah S,Ward JE,Bao R,Hall CR,Brockstein BE,Luke JJ

    更新日期:2016-11-01 00:00:00

  • Immunotargeting of the xCT Cystine/Glutamate Antiporter Potentiates the Efficacy of HER2-Targeted Immunotherapies in Breast Cancer.

    abstract::Despite HER2-targeted therapies improving the outcome of HER2+ breast cancer, many patients experience resistance and metastatic progression. Cancer stem cells (CSC) play a role in this resistance and progression, thus combining HER2 targeting with CSC inhibition could improve the management of HER2+ breast cancer. Th...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-20-0082

    authors: Conti L,Bolli E,Di Lorenzo A,Franceschi V,Macchi F,Riccardo F,Ruiu R,Russo L,Quaglino E,Donofrio G,Cavallo F

    更新日期:2020-08-01 00:00:00

  • Clonal Expansion and Interrelatedness of Distinct B-Lineage Compartments in Multiple Myeloma Bone Marrow.

    abstract::Multiple myeloma is characterized by the clonal expansion of malignant plasma cells in the bone marrow. But the phenotypic diversity and the contribution of less predominant B-lineage clones to the biology of this disease have been controversial. Here, we asked whether cells bearing the dominant multiple myeloma immun...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-17-0012

    authors: Hansmann L,Han A,Penter L,Liedtke M,Davis MM

    更新日期:2017-09-01 00:00:00

  • Possible Interaction of Anti-PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases.

    abstract::Delayed radiation-induced vasculitic leukoencephalopathy related to stereotactic radiosurgery (SRS) of brain metastases has been reported to manifest clinically 9 to 18 months after treatment. Immune-modulating therapies have been introduced to treatment regimens for malignancies with metastatic predilection to the br...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-15-0238

    authors: Alomari AK,Cohen J,Vortmeyer AO,Chiang A,Gettinger S,Goldberg S,Kluger HM,Chiang VL

    更新日期:2016-06-01 00:00:00

  • Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma.

    abstract::Ipilimumab and radiotherapy are commonly used to treat unresectable and metastatic melanoma. Results from preclinical studies and case reports suggest a biologic interaction between these two treatments. To understand the clinical implications of the interaction, we carried out a retrospective study reviewing records ...

    journal_title:Cancer immunology research

    pub_type: 杂志文章,评审

    doi:10.1158/2326-6066.CIR-13-0082

    authors: Barker CA,Postow MA,Khan SA,Beal K,Parhar PK,Yamada Y,Lee NY,Wolchok JD

    更新日期:2013-08-01 00:00:00

  • Tumor Cell-Intrinsic USP22 Suppresses Antitumor Immunity in Pancreatic Cancer.

    abstract::Although immune checkpoint blockade (ICB) improves clinical outcome in several types of malignancies, pancreatic ductal adenocarcinoma (PDA) remains refractory to this therapy. Preclinical studies have demonstrated that the relative abundance of suppressive myeloid cells versus cytotoxic T cells determines the efficac...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-19-0661

    authors: Li J,Yuan S,Norgard RJ,Yan F,Yamazoe T,Blanco A,Stanger BZ

    更新日期:2020-03-01 00:00:00

  • Quantification of Early-Stage Myeloid-Derived Suppressor Cells in Cancer Requires Excluding Basophils.

    abstract::Myeloid derived suppressor cells (MDSC) are a heterogeneous group of immature cells that accumulate in the peripheral blood and tumor microenvironment and are barriers to cancer therapy. MDSCs serve as prognostic biomarkers and are targets for therapy. On the basis of surface markers, three subsets of MDSCs have been ...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-19-0556

    authors: Khan ANH,Emmons TR,Wong JT,Alqassim E,Singel KL,Mark J,Smith BE,Tario JD,Eng KH,Moysich KB,Odunsi K,Abrams SI,Segal BH

    更新日期:2020-06-01 00:00:00

  • Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice.

    abstract::The prognosis is very dismal for patients with relapsed CD20(+) B-cell non-Hodgkin lymphoma (B-NHL). Facilitating the development of alternative novel therapeutic strategies is required to improve outcomes in patients with recurrent/refractory CD20(+) B-NHL. In this study, we investigated functional activities of anti...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-14-0114

    authors: Chu Y,Hochberg J,Yahr A,Ayello J,van de Ven C,Barth M,Czuczman M,Cairo MS

    更新日期:2015-04-01 00:00:00

  • Report on the Third FDA-AACR Oncology Dose-Finding Workshop.

    abstract::The FDA-AACR Oncology Dose-Finding Workshop, Part 3, was held in Washington, DC, on July 20, 2017, as a continuation of the previous two collaborative dose-finding and optimization workshops presented by the FDA and AACR. This year's workshop focused on combination therapy with immune-oncology agents and best practice...

    journal_title:Cancer immunology research

    pub_type:

    doi:10.1158/2326-6066.CIR-17-0590

    authors: Emens LA,Bruno R,Rubin EH,Jaffee EM,McKee AE

    更新日期:2017-12-01 00:00:00

  • Reflections on the Histopathology of Tumor-Infiltrating Lymphocytes in Melanoma and the Host Immune Response.

    abstract::In the past five decades, the role for lymphocytes in host immune response to tumors has been shown, at least in some patients, to be a critical component in disease prognosis. Also, the heterogeneity of lymphocytes has been documented, including the existence of regulatory T cells that suppress the immune response. A...

    journal_title:Cancer immunology research

    pub_type: 杂志文章,评审

    doi:10.1158/2326-6066.CIR-15-0143

    authors: Mihm MC Jr,Mulé JJ

    更新日期:2015-08-01 00:00:00

  • Anti-PD-1-Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma Patients.

    abstract::Pneumonitis may complicate anti-programmed death-1 (PD-1) therapy, although symptoms usually resolve with steroids. The long-term effects on respiratory function, however, are not well defined. We screened melanoma patients treated with anti-PD-1, with and without ipilimumab (anti-CTLA-4), and identified 31 patients w...

    journal_title:Cancer immunology research

    pub_type: 杂志文章,多中心研究

    doi:10.1158/2326-6066.CIR-18-0717

    authors: Johnson DB,Taylor KB,Cohen JV,Ayoubi N,Haugh AM,Wang DY,Schlick BD,Voorhees AL,Gage KL,Fintelmann FJ,Sullivan RJ,Eroglu Z,Abramson RG

    更新日期:2019-11-01 00:00:00

  • RORγt-Expressing Tregs Drive the Growth of Colitis-Associated Colorectal Cancer by Controlling IL6 in Dendritic Cells.

    abstract::Chronic inflammation drives colitis-associated colorectal cancer (CAC) in inflammatory bowel disease (IBD). FoxP3+ regulatory T cells (Treg) coexpressing the Th17-related transcription factor RORγt accumulate in the lamina propria of IBD patients, where they are thought to represent an intermediate stage of developmen...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-17-0698

    authors: Rizzo A,Di Giovangiulio M,Stolfi C,Franzè E,Fehling HJ,Carsetti R,Giorda E,Colantoni A,Ortenzi A,Rugge M,Mescoli C,Monteleone G,Fantini MC

    更新日期:2018-09-01 00:00:00

  • CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy.

    abstract::The transcription factor T-bet controls the Th1 genetic program in T cells for effective antitumor responses. Anti-CTLA-4 immunotherapy elicits dramatic antitumor responses in mice and in human patients; however, factors that regulate T-bet expression during an antitumor response mediated by anti-CTLA-4 remain to be e...

    journal_title:Cancer immunology research

    pub_type: 临床试验,杂志文章

    doi:10.1158/2326-6066.CIR-13-0155

    authors: Chen H,Fu T,Suh WK,Tsavachidou D,Wen S,Gao J,Ng Tang D,He Q,Sun J,Sharma P

    更新日期:2014-02-01 00:00:00

  • Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists.

    abstract::Hypoxia-driven, A2A adenosine receptor (A2AR)-mediated (hypoxia-A2-adenosinergic), T-cell-autonomous immunosuppression was first recognized as critical and nonredundant in protecting normal tissues from inflammatory damage and autoimmunity. However, this immunosuppressive mechanism can be highjacked by bacteria and tu...

    journal_title:Cancer immunology research

    pub_type: 杂志文章,评审

    doi:10.1158/2326-6066.CIR-14-0075

    authors: Sitkovsky MV,Hatfield S,Abbott R,Belikoff B,Lukashev D,Ohta A

    更新日期:2014-07-01 00:00:00

  • IL13-Mediated Dectin-1 and Mannose Receptor Overexpression Promotes Macrophage Antitumor Activities through Recognition of Sialylated Tumor Cells.

    abstract::Macrophage-mediated cytotoxicity is controlled by surface receptor expression and activation. Despite the numerous studies documenting the role of macrophage C-type lectin receptors (CLR) in pathogen elimination, little is known about their contribution to antitumor responses. Here, we report that IL13 inhibits T-cell...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-18-0213

    authors: Alaeddine M,Prat M,Poinsot V,Gouazé-Andersson V,Authier H,Meunier E,Lefèvre L,Alric C,Dardenne C,Bernad J,Alric L,Segui B,Balard P,Couderc F,Couderc B,Pipy B,Coste A

    更新日期:2019-02-01 00:00:00

  • Pathogen-driven cancers and emerging immune therapeutic strategies.

    abstract::Infectious agents play an etiologic role in approximately 20% of cancer cases worldwide. Eleven pathogens (seven viruses, three parasites, and one bacterium) are known to contribute to oncogenesis either directly via the expression of their protein products or indirectly via chronic inflammation. Although prevention o...

    journal_title:Cancer immunology research

    pub_type: 杂志文章,评审

    doi:10.1158/2326-6066.CIR-13-0179

    authors: Vandeven N,Nghiem P

    更新日期:2014-01-01 00:00:00

  • Escalating regulation of 5T4-specific IFN-γ+ CD4+ T cells distinguishes colorectal cancer patients from healthy controls and provides a target for in vivo therapy.

    abstract::The relationship between the adaptive CD4+ T cell response and human cancer is unclear. The oncofetal antigen 5T4 is expressed on many human carcinomas, including colorectal cancer (CRC) cells, but has limited expression on normal tissues. We previously identified anti-5T4 CD4+ T cells in a proportion of CRC patients,...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-13-0035

    authors: Scurr M,Bloom A,Pembroke T,Srinivasan R,Brown C,Smart K,Bridgeman H,Davies M,Hargest R,Phillips S,Christian A,Hockey T,Gallimore A,Godkin A

    更新日期:2013-12-01 00:00:00

  • An RNA Aptamer-Based Biomarker Platform Demonstrates High Soluble CD25 Occupancy by IL2 in the Serum of Follicular Lymphoma Patients.

    abstract::Ligand-receptor complexes play a central role in mediating a range of processes in immunology and cancer biology. The ability to directly quantify the fraction of receptors occupied by a ligand in a given biospecimen, as opposed to assessing the concentration of ligand and receptor separately, could provide an additio...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-18-0821

    authors: Veeramani S,Blackwell SE,Thiel WH,Yang ZZ,Ansell SM,Giangrande PH,Weiner GJ

    更新日期:2019-09-01 00:00:00

  • Insights into Tumor-Associated Tertiary Lymphoid Structures: Novel Targets for Antitumor Immunity and Cancer Immunotherapy.

    abstract::Tertiary lymphoid structures (TLS) are ectopic lymphoid aggregates that phenotypically resemble conventional secondary lymphoid organs and are commonly found at sites of chronic inflammation. They are also found in a wide variety of primary and metastatic human tumors. The presence of tumor-associated TLS (TA-TLS) is ...

    journal_title:Cancer immunology research

    pub_type: 杂志文章,评审

    doi:10.1158/2326-6066.CIR-20-0432

    authors: Rodriguez AB,Engelhard VH

    更新日期:2020-11-01 00:00:00

  • Integration of Oncogenes via Sleeping Beauty as a Mouse Model of HPV16+ Oral Tumors and Immunologic Control.

    abstract::Human papillomavirus type 16 (HPV16) is the etiologic factor for cervical cancer and a subset of oropharyngeal cancers. Although several prophylactic HPV vaccines are available, no effective therapeutic strategies to control active HPV diseases exist. Tumor implantation models are traditionally used to study HPV-assoc...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-16-0358

    authors: Lin YH,Yang MC,Tseng SH,Jiang R,Yang A,Farmer E,Peng S,Henkle T,Chang YN,Hung CF,Wu TC

    更新日期:2018-03-01 00:00:00

  • Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments.

    abstract::Chimeric antigen receptor (CAR) T-cell therapy is effective in the treatment of cancers of hematopoietic origin. In the immunosuppressive solid tumor environment, CAR T cells encounter obstacles that compromise their efficacy. We developed a strategy to address these barriers by having CAR T cells secrete single-domai...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-19-0734

    authors: Xie YJ,Dougan M,Ingram JR,Pishesha N,Fang T,Momin N,Ploegh HL

    更新日期:2020-04-01 00:00:00

  • Therapy of Established Tumors with Rationally Designed Multiple Agents Targeting Diverse Immune-Tumor Interactions: Engage, Expand, Enable.

    abstract::Immunotherapy of immunologically cold solid tumors may require multiple agents to engage immune effector cells, expand effector populations and activities, and enable immune responses in the tumor microenvironment (TME). To target these distinct phenomena, we strategically chose five clinical-stage immuno-oncology age...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-20-0638

    authors: Fabian KP,Malamas AS,Padget MR,Solocinski K,Wolfson B,Fujii R,Abdul Sater H,Schlom J,Hodge JW

    更新日期:2020-12-22 00:00:00

  • GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.

    abstract::Ligation of GITR (glucocorticoid-induced tumor necrosis factor (TNF) receptor-related gene, or TNFRSF18) by agonist antibody has recently entered into early phase clinical trials for the treatment of advanced malignancies. Although the ability of GITR modulation to induce tumor regression is well-documented in preclin...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-13-0086

    authors: Schaer DA,Budhu S,Liu C,Bryson C,Malandro N,Cohen A,Zhong H,Yang X,Houghton AN,Merghoub T,Wolchok JD

    更新日期:2013-11-01 00:00:00

  • Activated Eosinophils Exert Antitumorigenic Activities in Colorectal Cancer.

    abstract::Immunotherapies targeting T lymphocytes are revolutionizing cancer therapy but only benefit a subset of patients, especially in colorectal cancer. Thus, additional insight into the tumor microenvironment (TME) is required. Eosinophils are bone marrow-derived cells that have been largely studied in the context of aller...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-18-0494

    authors: Reichman H,Itan M,Rozenberg P,Yarmolovski T,Brazowski E,Varol C,Gluck N,Shapira S,Arber N,Qimron U,Karo-Atar D,Lee JJ,Munitz A

    更新日期:2019-03-01 00:00:00

  • Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer.

    abstract::In the context of cancer, naïve T cells are insufficiently primed and become progressively dysfunctional. Boosting antitumor responses by blocking PD-1 or CTLA-4 results in durable clinical responses only in a limited proportion of cancer patients, suggesting that other pathways must be targeted to improve clinical ef...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-15-0103-T

    authors: Bransi A,Salgado OC,Beffinger M,Milo K,Silina K,Yagita H,Becher B,Knuth A,van den Broek M

    更新日期:2015-11-01 00:00:00

  • Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome.

    abstract::The presence of regulatory T cells (Treg) in solid tumors is known to play a role in patient survival in ovarian cancer and other malignancies. We assessed inherited genetic variations via 749 tag single-nucleotide polymorphisms (SNP) in 25 Treg-associated genes (CD28, CTLA4, FOXP3, IDO1, IL10, IL10RA, IL15, 1L17RA, I...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-13-0136

    authors: Charbonneau B,Moysich KB,Kalli KR,Oberg AL,Vierkant RA,Fogarty ZC,Block MS,Maurer MJ,Goergen KM,Fridley BL,Cunningham JM,Rider DN,Preston C,Hartmann LC,Lawrenson K,Wang C,Tyrer J,Song H,deFazio A,Johnatty SE,Doher

    更新日期:2014-04-01 00:00:00

  • CAR-T Cells Surface-Engineered with Drug-Encapsulated Nanoparticles Can Ameliorate Intratumoral T-cell Hypofunction.

    abstract::One limiting factor of CAR T-cell therapy for treatment of solid cancers is the suppressive tumor microenvironment (TME), which inactivates the function of tumor-infiltrating lymphocytes (TIL) through the production of immunosuppressive molecules, such as adenosine. Adenosine inhibits the function of CD4+ and CD8+ T c...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-17-0502

    authors: Siriwon N,Kim YJ,Siegler E,Chen X,Rohrs JA,Liu Y,Wang P

    更新日期:2018-07-01 00:00:00

  • CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells.

    abstract::Natural killer (NK) cells contribute to clinical responses in patients treated with rituximab, but the rules determining NK-cell responsiveness to mAb therapies are poorly defined. A deeper understanding of the mechanisms responsible for antibody-dependent cellular cytotoxicity (ADCC) could yield useful biomarkers for...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-13-0158

    authors: Du J,Lopez-Verges S,Pitcher BN,Johnson J,Jung SH,Zhou L,Hsu K,Czuczman MS,Cheson B,Kaplan L,Lanier LL,Venstrom JM

    更新日期:2014-09-01 00:00:00

  • Inhibition of SHP-1 Expands the Repertoire of Antitumor T Cells Available to Respond to Immune Checkpoint Blockade.

    abstract::The presence and activity of CD8+ T cells within the tumor microenvironment are essential for the control of tumor growth. Utilizing B16-F10 melanoma tumors that express altered peptide ligands of chicken ovalbumin, OVA257-264, we measured high- and low-affinity OVA-specific responses following adoptive transfer of OT...

    journal_title:Cancer immunology research

    pub_type: 杂志文章

    doi:10.1158/2326-6066.CIR-19-0690

    authors: Snook JP,Soedel AJ,Ekiz HA,O'Connell RM,Williams MA

    更新日期:2020-04-01 00:00:00